Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Public ClinicalTrials.gov record NCT02732119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is determine if the triplet combination of ribociclib, everolimus and exemastane is safe and effective in the treatment of locally advanced/metastatic breast cancer following treatment with a CDK 4/6 inhibitor
Study identification
- NCT ID
- NCT02732119
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2016 (Actual)
- Primary completion
- Feb 25, 2020 (Actual)
- Completion
- Feb 25, 2020 (Actual)
- Last update posted
- May 5, 2021
2016 – 2020
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Centers Ironwood Cancer | Chandler | Arizona | 85224 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| UCLA Department of Medicine UCLA Hematology/Oncology | Los Angeles | California | 90095 | — |
| University of California San Francisco Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| Central Coast Medical Oncology Corporation Onc Dept | Santa Maria | California | 93454 | — |
| Yale University School of Medicine Smilow Cancer Hospital | New Haven | Connecticut | 06511 | — |
| Florida Cancer Research Institute Dept of Oncology | Davie | Florida | 33328 | — |
| Florida Cancer Specialists FL Cancer Specialists | Fort Myers | Florida | 33901 | — |
| UF Health Cancer Center at Orlando Health UF Health (4) | Orlando | Florida | 32806 | — |
| Florida Cancer Specialists-North | St. Petersburg | Florida | 33705 | — |
| Atlanta Cancer Center | Atlanta | Georgia | — | — |
| University of Kansas Cancer Center Univ of KS CC Medical Pavilion | Westwood | Kansas | 66205 | — |
| Massachusetts General Hospital Mass Gen Hos Cancer Center | Boston | Massachusetts | 02114 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| St. Luke's Cancer Institute Regulatory | Kansas City | Missouri | 64111 | — |
| Research Medical Center HCA Midwest Division | Kansas City | Missouri | 64132 | — |
| Washington University School of Medicine Washington U School of Medicin | St Louis | Missouri | 63110 | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| Penn State Hershey Cancer Institute | Hershey | Pennsylvania | 17033 | — |
| University of Pennsylvania Medical Center Abramson Cancer Ctr of the Uni | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute Sarah Cannon Research Insti | Nashville | Tennessee | 37203 | — |
| Oncology Consultants Oncology Consultants | Houston | Texas | 77024 | — |
| MD Anderson Cancer Center/University of Texas MDACC | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute Huntsman Cancer Insti | Salt Lake City | Utah | 84112 | — |
| Northwest Medical Specialties Dept of Onc | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02732119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2021 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02732119 live on ClinicalTrials.gov.